In a regulatory filing, Catalyst Pharmaceuticals (CPRX) president and CEO Richard Daly disclosed the purchase of 70,000 common shares of the company on May 30 at a price of $24.86 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharma Appoints New Chief Medical Officer
- Catalyst Pharmaceuticals appoints William Andrews as CMO
- Catalyst Pharma Holds 2025 Annual Stockholders Meeting
- Catalyst Pharma’s Strong Commercial Performance and Promising Revenue Guidance Justify Buy Rating
- Catalyst Pharma’s Strong Growth Prospects and Strategic Initiatives Drive Buy Rating